A single-center real-life study on the use of medical cannabis in patients with dystonia.
cannabidiol
delta-(9)-tetrahydrocannabinol
dystonia
medical cannabis
pain
treatment efficacy
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2023
2023
Historique:
received:
06
05
2023
accepted:
12
06
2023
medline:
17
7
2023
pubmed:
17
7
2023
entrez:
17
7
2023
Statut:
epublish
Résumé
While cannabis-based medicine is being commonly used in patients with movement disorders, there is a scarcity of publications regarding the effect of cannabis on dystonia. We aimed to describe medical cannabis use in patients with dystonia and related pain. We employed a structured interview to obtain data on the cannabis treatment regimen, perception of effectiveness and side effect profile. Eligible participants were patients diagnosed with dystonia from the movement disorders unit at the Tel-Aviv Medical Center who had used licensed medical cannabis between January 2019 and January 2021. Twenty-three subjects were interviewed (11 women, mean age 52.7). The most common way of administration was smoking ( A subset of dystonia patients who use medical cannabis under clinical observation reported significant subjective improvement during 30 months of use in average. Further prospective randomized controlled trials are required to examine the effectiveness of cannabis in dystonia.
Sections du résumé
Background
UNASSIGNED
While cannabis-based medicine is being commonly used in patients with movement disorders, there is a scarcity of publications regarding the effect of cannabis on dystonia. We aimed to describe medical cannabis use in patients with dystonia and related pain.
Methods
UNASSIGNED
We employed a structured interview to obtain data on the cannabis treatment regimen, perception of effectiveness and side effect profile. Eligible participants were patients diagnosed with dystonia from the movement disorders unit at the Tel-Aviv Medical Center who had used licensed medical cannabis between January 2019 and January 2021.
Results
UNASSIGNED
Twenty-three subjects were interviewed (11 women, mean age 52.7). The most common way of administration was smoking (
Conclusion
UNASSIGNED
A subset of dystonia patients who use medical cannabis under clinical observation reported significant subjective improvement during 30 months of use in average. Further prospective randomized controlled trials are required to examine the effectiveness of cannabis in dystonia.
Identifiants
pubmed: 37456642
doi: 10.3389/fneur.2023.1218300
pmc: PMC10339647
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1218300Informations de copyright
Copyright © 2023 Anis, Faust-Socher, Sverdlov, Lassman, Hezi, Anis, Leor, Korczyn, Giladi and Gurevich.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Parkinsonism Relat Disord. 2018 Sep;54:17-24
pubmed: 29724604
Clin Psychopharmacol Neurosci. 2017 Nov 30;15(4):301-312
pubmed: 29073741
J Clin Psychiatry. 2003 Apr;64(4):459-65
pubmed: 12716250
Int J Neurosci. 1986 Nov;30(4):277-82
pubmed: 3793381
Neurology. 2014 Apr 29;82(17):1556-63
pubmed: 24778283
Neuropharmacology. 2021 Jun 15;191:108586
pubmed: 33940011
Behav Neurol. 2022 Mar 9;2022:5141773
pubmed: 35310886
Clin Chem. 2011 Jan;57(1):66-75
pubmed: 21078841
Neurobiol Dis. 2019 Oct;130:104526
pubmed: 31279827
Mov Disord. 2015 Mar;30(3):313-27
pubmed: 25649017
Neurotherapeutics. 2008 Apr;5(2):198-209
pubmed: 18394563
Mov Disord. 2013 Jun 15;28(7):1001-12
pubmed: 23893456
Front Cell Neurosci. 2022 Feb 21;16:832854
pubmed: 35264932
J Neural Transm (Vienna). 2022 Oct;129(10):1247-1256
pubmed: 35859051
Mov Disord. 2002 Jan;17(1):145-9
pubmed: 11835452
Nat Rev Neurol. 2020 Jan;16(1):9-29
pubmed: 31831863
PLoS One. 2018 Feb 21;13(2):e0191436
pubmed: 29466446
Philos Trans R Soc Lond B Biol Sci. 2019 Nov 11;374(1785):20190279
pubmed: 31544609
Mov Disord. 2013 Jun 15;28(7):958-67
pubmed: 23893452
J Pharm Pharm Sci. 2020;23:
pubmed: 33064979
Graefes Arch Clin Exp Ophthalmol. 2022 May;260(5):1707-1712
pubmed: 35067772
Chem Biodivers. 2007 Aug;4(8):1770-804
pubmed: 17712819
J Pain Symptom Manage. 2002 Jul;24(1):4-6
pubmed: 12183086
Neurotherapeutics. 2015 Oct;12(4):788-92
pubmed: 26271953
Expert Opin Pharmacother. 2010 Jan;11(1):5-15
pubmed: 20001425
Mov Disord. 2005 Jan;20(1):113-5
pubmed: 15390041
J Neurophysiol. 2001 Jan;85(1):468-71
pubmed: 11152748
Mov Disord. 2009 Nov 15;24(15):2254-9
pubmed: 19845035
Neurol Sci. 2020 Apr;41(4):783-787
pubmed: 31848779